3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vascular Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Processes
1
Paraproteinemias
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Mullerian Mixed Tumor of Ovary
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Digestive System Neoplasms
1
Interventions
Dexamethasone
17
Bortezomib
11
pomalidomide
10
carfilzomib
6
Lenalidomide
4
imetelstat
3
fludarabine
3
daratumumab
3
Standard of Care
3
Panobinostat
3
venetoclax
2
siltuximab
2
elotuzumab
2
Cyclophosphamide
2
Arsenic Trioxide
2
spartalizumab
1
shark cartilage extract
1
selinexor
1
saracatinib
1
ricolinostat
1
resiquimod
1
poly ICLC
1
plitidepsin
1
pembrolizumab
1
pazopanib
1
motexafin gadolinium
1
marizomib
1
liposomal doxorubicin
1
lestaurtinib
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Plasma Cell
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled